Lehtinen Matti, Surcel Heljä-Marja, Natunen Kari, Pukkala Eero, Dillner Joakim
University of Tampere, Tampere, Finland.
Karolinska Institute, Stockholm, Sweden.
Cancer Med. 2017 Dec;6(12):3060-3064. doi: 10.1002/cam4.1222. Epub 2017 Oct 25.
Population-based Finnish Maternity Cohort (FMC) comprises 2M first trimester sera collected from 1M women during 33 years. Informed consent is by the opt-out principle, and linkages with cancer and population registries provide a base for over time and over generation studies. Follow-up for 17M person-years by the end of 2014 can identify 39,700 cases of invasive cancer and 18,900 cases of premalignant breast and cervix lesions, and basal cell carcinoma diagnosed after serum sampling. For women with multiple pregnancies, serial samples taken before cancer diagnosis are available. Offspring of the women have developed more than 4000 cancers. For 100,000 individuals, samples taken during the pregnancies of both their mothers and grandmothers enable familial cancer studies. FMC continues to collect samples, and surveillance of exposures or interventions like vaccination programs is feasible. In summary, the FMC is a unique, accessible biobank for epidemiological, biomarker, and surveillance studies on cancer.
基于人群的芬兰孕产妇队列（FMC）包含在33年期间从100万名女性中收集的200万份孕早期血清。知情同意遵循退出原则，与癌症和人口登记处的关联为长期和跨代研究提供了基础。到2014年底，1700万人年的随访能够识别出39700例浸润性癌症病例、18900例乳腺癌和宫颈癌癌前病变病例，以及血清采样后诊断出的基底细胞癌病例。对于多胎妊娠的女性，可获得癌症诊断前采集的系列样本。这些女性的后代已发生4000多种癌症。对于10万人而言，其母亲和祖母孕期采集的样本可用于家族性癌症研究。FMC继续收集样本，并且对疫苗接种计划等暴露或干预措施进行监测是可行的。总之，FMC是一个独特的、可利用的生物样本库，用于癌症的流行病学、生物标志物和监测研究。
